Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

The approval was based on data from the pivotal Phase IIb/III CLEVER trial which assessed a single dose of the antibody.

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

Africa's Department of Agriculture is urged to negotiate a new trade agreement with Brazil to ensure the continuous import of ...

Dr. Lbiati's appointment signals a new chapter for Hepion-one focused on strategic renewal, value creation, and diagnostic ...

Ten children died during the 2024-25 season, up from zero just five years ago. Experts say the spike comes as vaccination ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

The reluctance to get childhood immunizations comes amid a tumultuous period in Washington surrounding vaccine approvals.

For the first time since the start of the COVID-19 pandemic, the number of Nova Scotians dying from influenza exceeds that of ...